Last reviewed · How we verify

NCT05195502: COLATA

Mapping the Human Colon Using Single Cell Sequencing

Status unknown Last updated 8 February 2023
What this trial tests

trial testing Biopsy in Diabetes in 20 participants. Status unknown.

Timeline
1 July 2022
Primary endpoint
31 December 2022
1 July 2024

Quick facts

Lead sponsorBispebjerg Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date1 July 2022
Primary completion31 December 2022
Estimated completion1 July 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Bispebjerg Hospital

Who can join

18 and older, any sex, with Diabetes or Large Bowel Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall purpose of this study is to describe the cellular composition of the human colon and its gene expression using scRNAseq and scATACseq methods. This will potentially provide is with a detailed map of the colon aiding our understanding of how diseases of the colon develop as well as the colons influence on systemic diseases such as type II diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Biopsy

Trials testing the same drug.

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Bispebjerg Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing